{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:53:56Z","timestamp":1791726836189,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40123-026-01339-8","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:43:58Z","timestamp":1772354638000},"page":"1341-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Risk Factors of Ocular Hypertension Following Fluocinolone Acetonide (Iluvien\u00ae) Intravitreal Injections: The \u201cSAFAC\u201d Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Yasmine","family":"Serrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Sejournet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Allignet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Bounetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Deiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Gullon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Malcl\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"issue":"6","key":"1339_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1120672119857511","volume":"29","author":"L Kodjikian","year":"2019","unstructured":"Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29(6):573\u201384.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"1339_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.","journal-title":"Ophthalmology"},{"issue":"4","key":"1339_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.survophthal.2021.12.002","volume":"67","author":"R Jos\u00e9-Vieira","year":"2022","unstructured":"Jos\u00e9-Vieira R, Ferreira A, Men\u00e9res P, Sousa-Pinto B, Figueira L. Efficacy and safety of intravitreal and periocular injection of corticosteroids in noninfectious uveitis: a systematic review. Surv Ophthalmol. 2022;67(4):991\u20131013.","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"1339_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/bjophthalmol-2014-306159","volume":"99","author":"D Bellocq","year":"2015","unstructured":"Bellocq D, Korobelnik J-F, Burillon C, Voirin N, Dot C, Souied E, et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine\u2013Gass syndrome: the EPISODIC study. Br J Ophthalmol. 2015;99(7):979\u201383.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1339_CR5","doi-asserted-by":"publisher","first-page":".e2","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):.e2-635.e2.","journal-title":"Ophthalmology"},{"issue":"3","key":"1339_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583\u20137.","journal-title":"Ophthalmology"},{"key":"1339_CR7","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2147\/DDDT.S403259","volume":"17","author":"Y Mushtaq","year":"2023","unstructured":"Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD. Intravitreal fluocinolone acetonide implant (ILUVIEN\u00ae) for the treatment of retinal conditions. A review of clinical studies. Drug Des Dev Ther. 2023;17:961\u201375.","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"1339_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/archopht.1963.00960050484010","volume":"70","author":"MF Armaly","year":"1963","unstructured":"Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone* in the normal eye. Arch Ophthalmol. 1963;70(4):482\u201391.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1339_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000310780","volume":"211","author":"JR Polansky","year":"1997","unstructured":"Polansky JR, Fauss DJ, Chen P, Chen H, L\u00fctjen-Drecoll E, Johnson D, et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica. 1997;211(3):126\u201339.","journal-title":"Ophthalmologica"},{"issue":"7","key":"1339_CR10","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, Vi\u00e9 A-L, Agard \u00c9, Bellocq D, et al. Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37(7):1352\u20139.","journal-title":"Retina"},{"issue":"7","key":"1339_CR11","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1097\/IAE.0000000000003080","volume":"41","author":"A Rezkallah","year":"2021","unstructured":"Rezkallah A, Mathis T, Abukhashabah A, Voirin N, Malcl\u00e8s A, Agard \u00c9, et al. Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections: the SAFODEX-2 study. Retina. 2021;41(7):1438\u201345.","journal-title":"Retina"},{"issue":"6","key":"1339_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","volume":"129","author":"MA Singer","year":"2022","unstructured":"Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema. Ophthalmology. 2022;129(6):605\u201313.","journal-title":"Ophthalmology"},{"issue":"4","key":"1339_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics14040723","volume":"14","author":"T Mathis","year":"2022","unstructured":"Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, et al. Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real-life practice: the REALFAc study. Pharmaceutics. 2022;14(4):723.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1339_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40123-022-00504-z","volume":"11","author":"S Lebrize","year":"2022","unstructured":"Lebrize S, Arnould L, Bourredjem A, Busch C, Rehak M, Massin P, et al. Intraocular pressure changes after intravitreal fluocinolone acetonide implant: results from four european countries. Ophthalmol Ther. 2022;11(3):1217\u201329.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1339_CR15","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1177\/11206721221080288","volume":"32","author":"L Kodjikian","year":"2022","unstructured":"Kodjikian L, Bandello F, de Smet M, Dot C, Zarranz-Ventura J, Loewenstein A, et al. Fluocinolone acetonide implant in diabetic macular edema: International experts\u2019 panel consensus guidelines and treatment algorithm. Eur J Ophthalmol. 2022;32(4):1890\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1339_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","volume":"8","author":"A Eaton","year":"2019","unstructured":"Eaton A, Koh SS, Jimenez J, Riemann CD. The USER study: a chart review of patients receiving a 0.2 \u00b5g\/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8(1):51\u201362.","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"1339_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2023.05.001","volume":"46","author":"C Dot","year":"2023","unstructured":"Dot C, Poli M, Aptel F, Labbe A, Kodjikian L, Baillif S, et al. Ocular hypertension and intravitreal steroids injections, update in 2023. French guidelines of the French glaucoma society and the French ophthalmology society. J Fr Ophtalmol. 2023;46(8):e249\u2013e256.","journal-title":"J Fr Ophtalmol"},{"issue":"9","key":"1339_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jfo.2023.03.041","volume":"46","author":"J Billant","year":"2023","unstructured":"Billant J, Douma I, Agard E, Levron A, Bouvarel H, Leroux P, et al. Late steroid-induced ocular hypertension after intravitreal dexamethasone implants: a series of 20 cases. J Fr Ophtalmol. 2023;46(9):1039\u201346.","journal-title":"J Fr Ophtalmol"},{"issue":"9","key":"1339_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091756","volume":"14","author":"A Rezkallah","year":"2022","unstructured":"Rezkallah A, Kodjikian L, Barbarroux A, Laventure C, Motreff A, Chacun S, et al. Intra-ocular pressure response to dexamethasone implant injections in patients with a history of filtering surgery: the TRABEX study. Pharmaceutics. 2022;14(9):1756.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1339_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","volume":"58","author":"W Kiddee","year":"2013","unstructured":"Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58(4):291\u2013310.","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"1339_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bjophthalmol-2019-314559","volume":"104","author":"W Choi","year":"2020","unstructured":"Choi W, Bae HW, Choi EY, Kim M, Kim EW, Kim CY, et al. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population. Br J Ophthalmol. 2020;104(10):1423\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1339_CR22","doi-asserted-by":"crossref","unstructured":"Serrar Y, Sejournet L, Thomeret V, Dot C, Bonnin S, Soler V, et al. Efficacy and safety of multiple fluocinolone acetonide implants in diabetic macular oedema: comparison between first and second intravitreal injections. Eye. 2025;39:2678\u20132685.","DOI":"10.1038\/s41433-025-03929-5"},{"issue":"11","key":"1339_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0161-6420(00)00357-2","volume":"107","author":"JSK Ng","year":"2000","unstructured":"Ng JSK, Fan DSP, Young AL, Yip NKF, Tam K, Kwok AKH, et al. Ocular hypertensive response to topical dexamethasone in children. Ophthalmology. 2000;107(11):2097\u2013100.","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01339-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:42:20Z","timestamp":1775133740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01339-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01339-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasmine Serrar, Lucas Sejournet, Beno\u00eet Allignet, Sami Bounetta, Marwa Deiri, and Chlo\u00e9 Gullon have no conflict of interest to report. Laurent Kodjikian is consultant for AbbVie, Alimera, Bayer, Celltrion, MS-Pharma, Krys, Horus, Novartis, and Roche. Thibaud Mathis is consultant for AbbVie, Bayer, GSK, Horus, Kol, Novartis, and Roche. Philippe Denis is a consultant for AbbVie and Horus. Ariane Malcl\u00e8s is a consultant for Bayer and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This research was conducted in accordance with the Declaration of Helsinki. Patients' informed consent was obtained, and the local ethics committee (Hospices Civils de Lyon) approved the study, registered under number 20-156.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}